Research programme: antifungals - Elitra/Kaken
Alternative Names: Genomic Drug Discovery - Elitra/KakenLatest Information Update: 16 Mar 2009
Price :
$50 *
At a glance
- Originator Elitra Pharmaceuticals (CEASED); Kaken Pharmaceutical
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Aspergillosis; Candidiasis
Most Recent Events
- 16 Mar 2009 Discontinued - Preclinical for Aspergillosis in Japan (unspecified route)
- 16 Mar 2009 Discontinued - Preclinical for Aspergillosis in USA (unspecified route)
- 16 Mar 2009 Discontinued - Preclinical for Candidiasis in Japan (unspecified route)